Blood filtration for heart attack shock
Part of Heart & circulation clinical trials.
This trial tests a treatment called CRP apheresis, which filters a protein that causes inflammation from your blood during a heart attack complicated by cardiogenic shock. The goal is to reduce inflammation and improve recovery in people undergoing a heart procedure to open blocked arteries.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 80 years old.
- You have cardiogenic shock caused by a recent heart attack, meaning your blood pressure is very low and your organs are not getting enough blood.
- A heart procedure called PCI (also known as angioplasty) is planned or already happening to open the blocked artery.
- Your C-reactive protein (CRP) level is 7 mg/L or higher (this shows inflammation in your body).
- The cardiogenic shock started within the last 12 hours.
- You are not pregnant, do not have an active fever or infection, and have not had another interventional trial recently.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether using a small mechanical pump inside the heart plus careful monitoring with a special catheter can help people in shock after a heart attack. It compares this approach to standard care, aiming to improve survival and recovery.
This trial tests a new blood-filtering device called Efferon CT for people with cardiogenic shock after a heart attack. The device aims to help your body recover by cleaning harmful substances from your blood, and you might join if you are diagnosed early and don't have other serious health issues.
This trial studies specific body proteins to understand why fluid can leak from blood vessels during dangerous shock after infection or heart problems. If you (or your representative) qualify, your team will collect information and possibly samples to see whether these proteins relate to recovery and treatment response.
This trial tests a new kind of cell therapy made from donor cells that aims to reduce inflammation and help the heart recover after a severe heart attack. It's designed for people who are in cardiogenic shock (when the heart can't pump enough blood) despite having had emergency procedures like stents or bypass surgery.
This registry collects information from patients admitted to the hospital with cardiogenic shock—a serious condition where the heart cannot pump enough blood to the body. Doctors will gather data to better understand what happens to these patients and how to improve their care.
This trial tests whether a blood-cleaning procedure called CRP apheresis, given after a first heart attack, can improve recovery when a heart-attack blood marker (CRP) is high. It’s aimed at people whose heart attack is treated quickly with a procedure to open blocked arteries, and who are well enough for heart MRI scans.
Hear when a new Cardiogenic Shock trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.